Insider Selling: Twist Bioscience (NASDAQ:TWST) CEO Sells $147,396.16 in Stock

Twist Bioscience Corporation (NASDAQ:TWST) CEO Emily Leproust sold 1,688 shares of Twist Bioscience stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $87.32, for a total transaction of $147,396.16. Following the completion of the sale, the chief executive officer owned 842,919 shares of the company’s stock, valued at $73,603,687.08. This trade represents a 0.20% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Twist Bioscience Trading Up 3.3%

Shares of Twist Bioscience stock opened at $99.84 on Friday. The company has a current ratio of 2.70, a quick ratio of 2.42 and a debt-to-equity ratio of 0.03. Twist Bioscience Corporation has a 12-month low of $23.30 and a 12-month high of $104.23. The firm has a market capitalization of $6.22 billion, a price-to-earnings ratio of -75.07 and a beta of 2.23. The firm’s 50 day simple moving average is $67.01 and its two-hundred day simple moving average is $51.44.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings data on Monday, May 4th. The company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.22). The company had revenue of $110.72 million for the quarter, compared to analyst estimates of $107.64 million. Twist Bioscience had a negative return on equity of 26.73% and a negative net margin of 19.85%.The company’s quarterly revenue was up 19.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.66) earnings per share. Analysts predict that Twist Bioscience Corporation will post -2.02 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have commented on TWST shares. Canaccord Genuity Group started coverage on Twist Bioscience in a research report on Monday, June 15th. They set a “buy” rating and a $90.00 price target for the company. TD Cowen increased their price objective on Twist Bioscience from $68.00 to $89.00 and gave the company a “buy” rating in a report on Monday, June 15th. Piper Sandler began coverage on Twist Bioscience in a research note on Thursday, June 11th. They issued an “overweight” rating and a $85.00 price objective for the company. Leerink Partners set a $80.00 target price on Twist Bioscience in a report on Friday, May 22nd. Finally, Robert W. Baird upped their target price on Twist Bioscience from $50.00 to $65.00 and gave the company an “outperform” rating in a research report on Tuesday, May 5th. Nine research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Twist Bioscience has an average rating of “Moderate Buy” and a consensus price target of $74.60.

Institutional Investors Weigh In On Twist Bioscience

Several hedge funds have recently added to or reduced their stakes in TWST. Western Wealth Management LLC acquired a new stake in Twist Bioscience during the 1st quarter worth about $31,000. Strs Ohio acquired a new position in shares of Twist Bioscience in the 1st quarter valued at about $33,000. PNC Financial Services Group Inc. boosted its stake in shares of Twist Bioscience by 89.7% in the first quarter. PNC Financial Services Group Inc. now owns 958 shares of the company’s stock worth $46,000 after buying an additional 453 shares during the last quarter. Quarry LP purchased a new stake in shares of Twist Bioscience in the third quarter worth about $28,000. Finally, Strategic Advocates LLC grew its holdings in Twist Bioscience by 562.7% during the fourth quarter. Strategic Advocates LLC now owns 1,067 shares of the company’s stock worth $34,000 after acquiring an additional 906 shares during the period.

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.